Key Points
- Director Todd Thomson sold 280,000 shares at an average price of $5.80 for proceeds of $1,624,000, cutting his stake by 23.63% to 904,795 shares (worth about $5.25M).
- Actuate opened at $6.49 with a market capitalization of $150.8M and a negative P/E, trading in a one‑year range of $5.47 to $11.99 and 50/200‑day SMAs near $6.62/$7.00.
- Analysts are mixed—three Buy ratings and one Sell—yielding a consensus of Moderate Buy and an average price target of $20.33.
Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) Director Todd Thomson sold 280,000 shares of the company's stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $5.80, for a total value of $1,624,000.00. Following the sale, the director owned 904,795 shares in the company, valued at approximately $5,247,811. This trade represents a 23.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Actuate Therapeutics Price Performance
NASDAQ:ACTU opened at $6.49 on Thursday. The firm has a market capitalization of $150.83 million, a price-to-earnings ratio of -7.46 and a beta of -0.15. The business has a 50 day simple moving average of $6.62 and a 200-day simple moving average of $7.00. Actuate Therapeutics, Inc. has a 1 year low of $5.47 and a 1 year high of $11.99.
Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.02.
Analysts Set New Price Targets
ACTU has been the subject of several analyst reports. Wall Street Zen upgraded shares of Actuate Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. Weiss Ratings reissued a "sell (e+)" rating on shares of Actuate Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Actuate Therapeutics in a research report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $20.33.
Get Our Latest Stock Analysis on ACTU
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Sfmg LLC lifted its holdings in Actuate Therapeutics by 32.3% during the 2nd quarter. Sfmg LLC now owns 14,550 shares of the company's stock valued at $89,000 after buying an additional 3,550 shares in the last quarter. Bank of America Corp DE increased its position in shares of Actuate Therapeutics by 61,068.0% during the second quarter. Bank of America Corp DE now owns 15,292 shares of the company's stock worth $93,000 after acquiring an additional 15,267 shares during the period. New York State Common Retirement Fund purchased a new position in shares of Actuate Therapeutics during the second quarter worth approximately $105,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Actuate Therapeutics by 492.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company's stock valued at $113,000 after acquiring an additional 15,393 shares in the last quarter. Finally, Gleason Group Inc. purchased a new stake in shares of Actuate Therapeutics in the second quarter valued at approximately $116,000.
About Actuate Therapeutics
(
Get Free Report)
Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.
The company's lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
